Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN VK versus POLYCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN VK versus POLYCILLIN.
PENICILLIN-VK vs POLYCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Polycillin (ampicillin) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
250-500 mg orally every 6 hours or 500 mg intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 0.5-1 hour in adults with normal renal function; prolonged to 7-10 hours in anuria.
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Renal excretion of unchanged drug accounts for 60-80% via glomerular filtration and tubular secretion; 20-40% is hepatically metabolized and eliminated in bile/feces.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic